Association of platelet-activating factor with primary acquired cold urticaria.

We investigated the possibility that the inflammatory reaction in primary acquired cold urticaria might be associated with the release of platelet-activating factor. Six patients with the disease and five normal controls were subjected to cold-water challenges during which blood samples were obtained for measurement of the release of possible mediators: i.e., histamine, neutrophilic chemotactic activity, and platelet-activating factor-like lipid (PAF-LL). Four of the patients had pronounced experimentally induced cold urticaria with angioedema and release of mediators. Levels of the three mediators were not elevated in five normal controls or in two patients in whom cold challenges induced only mild urticaria and angioedema. The effective suppression of cold-induced urticaria in three patients treated with doxepin correlated with inhibition of PAF-LL release but not inhibition of histamine or neutrophilic chemotactic activity release. These data suggest a positive correlation between PAF-LL release and cold urticaria, although the exact relation between PAF-LL and cutaneous lesions of primary acquired cold urticaria has not yet been established.

[1]  M. Ginsberg,et al.  Release of platelet factor 4 into the blood after cold challenge of patients with cold urticaria. , 1984, The Journal of allergy and clinical immunology.

[2]  D. Lenihan,et al.  Increased biosynthesis of platelet-activating factor in activated human eosinophils. , 1984, The Journal of biological chemistry.

[3]  D. Macdonald,et al.  Inflammatory characteristics of platelet activating factor (PAF‐acether) in human skin , 1984, The British journal of dermatology.

[4]  R. N. Pinckard Platelet-activating factor. , 1983, Hospital practice.

[5]  R. Vukovich,et al.  Preliminary report on the effects of tiaramide on the ice cube test in patients with idiopathic cold urticaria. , 1983, Annals of allergy.

[6]  K. Austen,et al.  The functional and physicochemical characterization of three eosinophilotactic activities released into the circulation by cold challenge of patients with cold urticaria. , 1982, Clinical and experimental immunology.

[7]  L. McManus,et al.  Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[8]  R. Eady,et al.  Dissociation of histamine release and clinical improvement following treatment of acquired cold urticaria by prednisone. , 1981, British journal of clinical pharmacology.

[9]  R. Farr,et al.  The presence of platelet-activating factor (PAF) in normal human mixed saliva. , 1981, Journal of Immunology.

[10]  P. Henson,et al.  Production and release of platelet-activating factor (PAF); dissociation from degranulation and superoxide production in the human neutrophil. , 1980, Journal of immunology.

[11]  J. Benveniste,et al.  Release of platelet‐activating factor (PAF‐acether) from alveolar macrophages by the calcium ionophore A 23187 and phagocytosis , 1980, European journal of clinical investigation.

[12]  A. Kaplan,et al.  The role of cyproheptadine in the treatment of cold urticaria. , 1980, The Journal of allergy and clinical immunology.

[13]  P. Henson,et al.  Human neutrophil-derived platelet activating factor. , 1980, Journal of immunology.

[14]  D. Hanahan,et al.  Physical and chemical properties of platelet-activating factor obtained from human neutrophils and monocytes and rabbit neutrophils and basophils. , 1980, Biochimica et biophysica acta.

[15]  F. Snyder,et al.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. , 1979, Biochemical and biophysical research communications.

[16]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[17]  D. Hanahan,et al.  Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. , 1979, Journal of immunology.

[18]  E. Richelson Tricyclic antidepressants and histamine H1 receptors. , 1979, Mayo Clinic proceedings.

[19]  B. Vargaftig,et al.  The role of platelet-activating factor in platelet aggregation , 1979, Nature.

[20]  G. Camussi,et al.  Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. , 1977, Immunology.

[21]  E. Ellis,et al.  Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. , 1977, Archives of dermatology.

[22]  K.,et al.  Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge. , 1977, The Journal of clinical investigation.

[23]  A. Kaplan,et al.  In vivo studies of mediator release in cold urticaria and cholinergic urticaria. , 1975, The Journal of allergy and clinical immunology.

[24]  P. Henson,et al.  LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETS THE ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR , 1972 .

[25]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[26]  B. Rose Studies on blood histamine in cases of allergy: I. Blood histamine during wheal formation , 1941 .

[27]  George E. Brown,et al.  HYPERSENSITIVENESS TO COLD: WITH LOCAL AND SYSTEMIC MANIFESTATIONS OF A HISTAMINE-LIKE CHARACTER: ITS AMENABILITY TO TREATMENT , 1936 .